All Posts
[Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7% for Pfizer and 100.0% for Moderna.
12 Aug, 2021 | 09:53h | UTCRelated:
Commentary on Twitter
New and important data on Delta breakthrough infections, large Qatar experience and follow-up of > 1.2 million vaccinees https://t.co/2ye1Kz9OPV
2-doses vaccine effectiveness vs infections
Pfizer 53.5%
Moderna 84.8%
Either 57.2%
(replicates gap of recent Mayo Clinic study) pic.twitter.com/ghWuWbYPLH— Eric Topol (@EricTopol) August 11, 2021
WHO’s Solidarity clinical trial enters a new phase with three new candidate drugs.
12 Aug, 2021 | 09:02h | UTCCommentary:
WHO-led Trial Will Test Malaria and Cancer Medicines Against COVID-19 – Health Policy Watch
Related:
WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.
Commentary on Twitter (thread – click for more)
WHO’s #COVID19 Solidarity clinical trial enters a new phase – Solidarity PLUS – with three new candidate drugs:
-artesunate
-imatinib
-infliximab— World Health Organization (WHO) (@WHO) August 11, 2021
Video: Frequently Asked COVID-19 Vaccine Questions – August 2021 Update.
12 Aug, 2021 | 08:59h | UTCFrequently Asked COVID-19 Vaccine Questions – August 2021 Update – JAMA
Vaccination: Effectiveness versus Efficacy.
12 Aug, 2021 | 09:01h | UTCVaccination: Effectiveness versus Efficacy – by Luis Correa, MD
Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.
12 Aug, 2021 | 09:05h | UTCCommentary: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD
Related:
NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Commentary on Twitter
The phenotypes of VITT were defined in 220 patients presenting a 14-day median after the first ChAdOx1 nCoV-19 dose. Mortality was 22%. https://t.co/ir0yG5X0BP #COVID19 #IDTwitter pic.twitter.com/iAfxs0I1Ce
— NEJM (@NEJM) August 11, 2021
Guideline: Diagnosis and management of cutaneous lupus erythematosus – Therapy, risk factors and other special topics.
12 Aug, 2021 | 08:55h | UTC
Peripartum cardiomyopathy: from genetics to management.
12 Aug, 2021 | 08:47h | UTCPeripartum cardiomyopathy: from genetics to management – European Heart Journal
Related:
Review: Cardiomyopathy and Pregnancy (guidelines and reviews)
Commentary on Twitter
Must read review: peripartum cardiomyopathy, from genetics to management https://t.co/viVa7AbWsn@escardio #EHJ #ESCYoung #cardiotwitter #heartfailure #pregnancy @ehj_ed @rladeiraslopes pic.twitter.com/dfUi1jYxHB
— European Society of Cardiology Journals (@ESC_Journals) August 11, 2021
ASCO Guideline Update: Chemotherapy and Targeted Therapy for Patients with Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative.
12 Aug, 2021 | 08:52h | UTC
2021 guidelines for management of venous thromboembolism in Latin America.
12 Aug, 2021 | 08:56h | UTC
ESMO Guideline: Cancer cachexia in adult patients.
12 Aug, 2021 | 08:53h | UTC
Review: Diagnosis of uncomplicated and complicated appendicitis in adults.
12 Aug, 2021 | 08:45h | UTCDiagnosis of Uncomplicated and Complicated Appendicitis in Adults – Scandinavian Journal of Surgery
Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement.
12 Aug, 2021 | 08:49h | UTCCommentary: TAVR still comparable to surgery after 8 years – Cardiovascular Business
Commentary on Twitter
Long term results from NOTION, out to 8 years. #TAVR #SAVR #EHJhttps://t.co/V75hG0cGNQ pic.twitter.com/0CFNPmixNW
— EHJ Editor-in-Chief (@ehj_ed) August 11, 2021
RCT: Injectable long-acting Cabotegravir for HIV prevention in cisgender men and transgender women.
12 Aug, 2021 | 08:51h | UTC
Vaccines given in last 20 years could prevent 50 million deaths in LMICs.
12 Aug, 2021 | 08:43h | UTCVaccines given in last 20 years could prevent 50 million deaths in LMICs – Imperial College London
Original study: Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world – eLife
Artificial intelligence projects in healthcare: 10 practical tips for success in a clinical environment.
12 Aug, 2021 | 08:44h | UTC
Adverse events and hospital-acquired conditions associated with potential low-value care in Medicare beneficiaries.
12 Aug, 2021 | 08:42h | UTCCommentary: Hospital overuse linked to thousands of adverse events each year – Lown Institute
Commentary on Twitter (thread – click for more)
Research by @kelsey_chalmers @AElshaug @DrVikasSaini @ShannonBrownlee shows that spinal fusion overuse is associated with >1000 more adverse events for Medicare beneficiaries each year.https://t.co/L83CDNqFiC
— Lown Institute (@lowninstitute) July 27, 2021
Brief review: Nails in systemic disease.
12 Aug, 2021 | 08:40h | UTCNails in systemic disease – Clinical Medicine Journal
Brief review: Immunobullous disease.
12 Aug, 2021 | 08:37h | UTCImmunobullous disease – Clinical Medicine Journal
Psoriasis: a brief overview.
12 Aug, 2021 | 08:39h | UTCPsoriasis: a brief overview – Clinical Medicine Journal
Brief review: Advances in atopic dermatitis.
12 Aug, 2021 | 08:32h | UTCAdvances in atopic dermatitis – Clinical Medicine Journal
Cutaneous manifestations of infections: an update for general physicians.
12 Aug, 2021 | 08:36h | UTCCutaneous manifestations of infections: an update for general physicians – Clinical Medicine Journal
M-A: Asymptomatic SARS-CoV-2 infection – “we estimate that the percentage of infections that never developed clinical symptoms, and thus were truly asymptomatic, was 35.1%”.
11 Aug, 2021 | 08:49h | UTC
Commentary on Twitter
The best comprehensive review of the asymptomatic status with Covid, >350 studies, just out @PNASNews https://t.co/xyfgyGXANL
Overall: true, never had symptoms 35%; children 47%@Pratha_Sah @Alison_Galvani @MeaganCFitz @YaleSPH & colleagues
(wonder what the rate is w/ Delta) pic.twitter.com/9W6wbvQno6— Eric Topol (@EricTopol) August 10, 2021
PRINCIPLE RCT: Inhaled budesonide improves time to recovery from COVID-19 in people at high risk of complications in the community.
11 Aug, 2021 | 08:52h | UTCInvited Commentary: The use of inhaled corticosteroids in early-stage COVID-19
WHO Guidance for surveillance of SARS-CoV-2 variants.
11 Aug, 2021 | 08:50h | UTC
Commentary on Twitter (thread – click for more)
🆕 WHO guidance for national surveillance of #COVID19 virus variants 👉https://t.co/YHRsazZhPA
Standardizing the monitoring & reporting of the variants will give us a better understanding of the virus at a global scale. pic.twitter.com/VNcxv8gyaa
— World Health Organization (WHO) (@WHO) August 10, 2021
M-A: More than 50 long-term effects of COVID-19.
11 Aug, 2021 | 08:47h | UTCRelated:
Cohort study: Risk factors for long covid in previously hospitalized children.
Viewpoint: The road to addressing Long Covid.
Review: Long covid—mechanisms, risk factors, and management.
Review: Symptoms, complications and management of long COVID.
Studies elucidate poorly understood long COVID.
Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.
[Preprint] Long Covid: Third of people infected have long term symptoms.
Almost 25% of COVID-19 patients develop long-lasting symptoms, according to a new report.
Perspective | The four most urgent questions about long COVID.
Systematic review: Frequency, signs and symptoms, and criteria adopted for long COVID-19.
Report: 376,000 people in UK have had long Covid symptoms for at least a year.
One third of patients hospitalized with COVID-19 have lung changes after a year
Perspective | They Tested Negative for Covid. Still, They Have Long Covid Symptoms.
Cohort study: One in ten have long-term effects 8 months following mild COVID-19
Long Covid Implications for the workplace
Long Covid in the UK – More than a million affected in February, survey suggests
Covid-19: Middle aged women face greater risk of debilitating long term symptoms
Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”
Review | Post-acute COVID-19 syndrome
Long Covid | Four-month clinical status of a cohort of patients after hospitalization for COVID-19
Perspective | Long Covid isn’t as unique as we thought
Attributes and predictors of long COVID
WHO Report: Preparing for Long COVID 2021
Long Covid: Sequelae in adults at 6 Months after COVID-19 infection
How many people get ‘long COVID’ – and who is most at risk?
Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline
Patients, clinicians seek answers to the mystery of ‘Long COVID’
Long Covid: 6-month consequences of COVID-19 in patients discharged from hospital
NICE Guideline: Managing the long-term effects of COVID-19
Commentary on Twitter
https://twitter.com/svillapol/status/1425032774793285648